Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting

Jennifer G. Goldman*, Bradley F. Boeve, Melissa J. Armstrong, Doug R. Galasko, James E. Galvin, David J. Irwin, James B. Leverenz, Karen Marder, Victor Abler, Kevin Biglan, Michael C. Irizarry, Bill Keller, Robert Lai, Leanne Munsie, Michael Belleville, Ondrea Chaney, Ian Richard, Angela Taylor, Todd Graham

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments. At the second annual meeting of the Industry Advisory Council, held virtually on June 18, 2020, the key members presented ongoing and planned efforts toward the council’s goals. The meeting also featured a discussion about the effects of the COVID-19 pandemic on Lewy body dementia clinical research, lessons learned from that experience, and how those lessons can be applied to the design and conduct of future clinical trials. This report provides a brief summary of the meeting proceedings with a focus on efforts to improve and adapt future Lewy body dementia clinical research.

Original languageEnglish (US)
Article number124
JournalAlzheimer's Research and Therapy
Volume13
Issue number1
DOIs
StatePublished - Dec 2021

Keywords

  • Clinical trial
  • COVID-19
  • Lewy body dementia
  • Research
  • Telemedicine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Fingerprint

Dive into the research topics of 'Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting'. Together they form a unique fingerprint.

Cite this